Trial Profile

Phase 1/1b Multicenter Open-Label Study of RMC-6236 in Subjects With Advanced Solid Tumors Harboring Specific Mutations in KRAS

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 09 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Daraxonrasib (Primary)
Indications Adenocarcinoma; Colorectal cancer; Non-small cell lung cancer; Pancreatic ductal carcinoma; Solid tumours
Focus Adverse reactions; First in man; Proof of concept
Sponsors REVOLUTION Medicines

30 Apr 2025 Results of exploratory analysis assessing reduction in circulating tumor DNA (ctDNA) from patients with NSCLC treated with daraxonrasib presented at the 116th Annual Meeting of the American Association for Cancer Research
02 Dec 2024 According to a Revolution Medicines media release, company announced key clinical data updates from this study to be presented during an investor webcast today at 8:00 a.m. Eastern Time (ET).
02 Dec 2024 Results presented in the Revolution Medicines Media Release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com